Q1 Earnings Forecast for Biogen Issued By Leerink Partnrs

Biogen Inc. (NASDAQ:BIIB) – Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Biogen in a research note issued to investors on Wednesday, February 12th. Leerink Partnrs analyst M. Goodman anticipates that the biotechnology company will earn $3.84 per share for the quarter. The consensus estimate for Biogen’s current full-year earnings is $16.42 per share. Leerink Partnrs also issued estimates for Biogen’s Q2 2025 earnings at $4.10 EPS, Q3 2025 earnings at $3.90 EPS, Q4 2025 earnings at $4.01 EPS, FY2025 earnings at $15.85 EPS, FY2026 earnings at $16.45 EPS, FY2027 earnings at $16.40 EPS, FY2028 earnings at $17.65 EPS and FY2029 earnings at $19.50 EPS.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01. Biogen had a net margin of 16.81% and a return on equity of 14.98%.

BIIB has been the subject of a number of other research reports. Mizuho reduced their price objective on Biogen from $251.00 to $207.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Canaccord Genuity Group decreased their price target on shares of Biogen from $298.00 to $265.00 and set a “buy” rating for the company in a research note on Thursday. HC Wainwright dropped their price objective on shares of Biogen from $300.00 to $241.00 and set a “buy” rating on the stock in a research note on Thursday. JPMorgan Chase & Co. decreased their target price on shares of Biogen from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Monday, November 4th. Finally, Bank Of America (Bofa) dropped their price target on shares of Biogen from $178.00 to $163.00 and set a “neutral” rating on the stock in a research report on Tuesday. Seventeen equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to data from MarketBeat, Biogen has a consensus rating of “Hold” and an average price target of $211.96.

Biogen Stock Performance

Shares of Biogen stock opened at $138.45 on Friday. The business has a 50-day simple moving average of $147.73 and a 200 day simple moving average of $174.05. Biogen has a one year low of $128.51 and a one year high of $238.00. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. The firm has a market capitalization of $20.17 billion, a price-to-earnings ratio of 12.51, a PEG ratio of 1.65 and a beta of -0.08.

Institutional Trading of Biogen

Several hedge funds have recently made changes to their positions in the company. Exchange Traded Concepts LLC increased its holdings in Biogen by 4,516.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 1,662 shares of the biotechnology company’s stock worth $322,000 after acquiring an additional 1,626 shares during the last quarter. Swedbank AB boosted its position in Biogen by 85.0% during the third quarter. Swedbank AB now owns 185,008 shares of the biotechnology company’s stock worth $35,862,000 after purchasing an additional 84,981 shares during the period. Kapitalo Investimentos Ltda purchased a new position in shares of Biogen in the third quarter worth about $227,000. Sumitomo Life Insurance Co. raised its position in shares of Biogen by 4.3% in the third quarter. Sumitomo Life Insurance Co. now owns 3,906 shares of the biotechnology company’s stock valued at $757,000 after purchasing an additional 162 shares during the period. Finally, nVerses Capital LLC bought a new position in Biogen in the 3rd quarter worth approximately $388,000. 87.93% of the stock is currently owned by institutional investors.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.